[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100649168":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":27,"responsibleParty":46,"collaborators":20,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":54,"acronym":20,"eligibilityCriteria":55,"healthyVolunteers":52,"sex":56,"minAge":57,"maxAge":20,"enrollmentInfo":58,"targetDuration":20,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":67,"overallStatus":30,"whyStopped":20,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},{"fullName":5,"class":6},"Beaumont Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Blood Brain Barrier Characterisation Cohort","EXPERIMENTAL","Participants with newly diagnosed glioblastoma will undergo a standardized Phase 2 multimodal assessment program designed to characterize blood-brain barrier integrity. Study interventions include serial advanced contrast-enhanced MRI, blood biomarker sampling, neurocognitive assessments, and molecular analysis of tumor tissue obtained during standard of care surgical resection. Assessments will be performed longitudinally at predefined time points before surgery, after surgery, at 72 hours, at 4 weeks, and following completion of radiotherapy to evaluate changes in blood-brain barrier function and their association with clinical, radiological, and molecular outcomes.",[13],"Diagnostic Test: Multimodal Blood Brain Barrier Assessment",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DIAGNOSTIC_TEST","Multimodal Blood Brain Barrier Assessment","A standardised multimodal diagnostic assessment designed to characterize blood brain barrier integrity in patients with newly diagnosed glioblastoma. The intervention includes advanced contrast enhanced MRI, serial blood sampling for measurement of blood-brain barrier and neuronal injury biomarkers (including S100β, GFAP, UCHL1, amyloid beta, phosphorylated tau, and neuron-specific enolase), neurocognitive assessments, and immunohistochemical and transcriptional analyses of tumor tissue obtained during standard-of-care surgical resection. Assessments are performed longitudinally before surgery, after surgery, at 72 hours, at 4 weeks, and following completion of radiotherapy.",[9],null,[22],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Professor Donncha O'Brien, MB, BCh, BAO, MCh, FRCSI (SN)","CONTACT","018093000","cancerdirectorate@beaumont.ie",[28],{"facility":29,"status":30,"city":31,"state":20,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"Beaumont RCSI Cancer Centre","RECRUITING","Beaumont","D09","Ireland","IE",{"type":36,"coordinates":37},"Point",[38,39],-6.22713,53.38721,{"lat":39,"lon":38},[42],{"name":43,"role":24,"phone":44,"phoneExt":20,"email":45},"Aisling Hegarty, RGN, BSc, MSc, PhD","017977800","Aislinghegarty@rcsi.ie",{"type":47,"investigatorFullName":48,"investigatorTitle":49,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"SPONSOR_INVESTIGATOR","Patrick Morris","Clinical Director Cancer Clinical Trials Unit","100649168","characterization-of-the-blood-brain-barrier-in-high-grade-glioma-through-immunohistochemical-transcriptional-fluorescein-and-radiological-analyses-100649168",false,"NCT07731555","Characterization of the Blood-Brain Barrier in High-Grade Glioma Through Immunohistochemical, Transcriptional, Fluorescein and Radiological Analyses","Inclusion Criteria:\n\n* Adult patients aged 18 years or older.\n* Newly diagnosed glioblastoma.\n* Selected for surgical tumor resection.\n* Able and willing to provide written informed consent.\n* Able to undergo study assessments and follow-up procedures.\n\nExclusion Criteria:\n\n* Contraindication to magnetic resonance imaging.\n* Confusion, delirium, or altered state of consciousness that interferes with the ability to provide informed consent.\n* Any condition that, in the opinion of the investigator, would prevent completion of study procedures or compromise participant safety.","ALL","18 Years",{"count":59,"type":60},100,"ESTIMATED","INTERVENTIONAL",[63],"NA","This prospective study aims to characterize blood brain barrier (BBB) disruption in patients with newly diagnosed glioblastoma multiforme undergoing surgical resection. The study integrates advanced MRI, circulating BBB biomarkers, neurocognitive assessment, and molecular analysis of tumor tissue to investigate relationships between BBB integrity, tumor biology, and neurological function. Participants will undergo serial assessments before surgery, after surgery, and following radiotherapy. Tumor tissue collected during standard-of-care resection will undergo immunohistochemical and transcriptional",[66],"Glioblastoma",[68,66,69],"Blood Brain Barrier","High Grade Glioma","2026-07-25",{"date":72,"type":73},"2026-07-28","ACTUAL",{"date":75,"type":73},"2022-03-01",{"date":77,"type":60},"2035-12-31",{"name":48,"class":6},1]